Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : REFILE-UPDATE 2-EU has not ordered AstraZeneca vaccines beyond June - Commissioner

05/09/2021 | 08:27am EDT

PARIS, May 9 (Reuters) - The European Union has not made any new orders for AstraZeneca vaccines beyond June when their contract ends, European Internal Market Commissioner Thierry Breton said on Sunday, after the EU signed a deal with Pfizer-BioNTech.

Breton also said he expected the costs of the Pfizer-BioNTech vaccines to be higher than the earlier versions.

The Commission last month launched legal action against AstraZeneca for not respecting its contract for the supply of COVID-19 vaccines and for not having a "reliable" plan to ensure timely deliveries. "We did not renew the order after June. We’ll see what happens," Breton told France Inter radio. He did not rule out a potential renewal at a later stage.

Concerns have risen on potential side-effects of the Anglo-Swedish COVID-19 vaccine.

Europe's medicines regulator said on Friday it is reviewing reports of a rare nerve-degenerating disorder in people who received the shots, a move that comes after it found the vaccine may have caused very rare blood clotting cases.

While the regulator has maintained that the benefits of the AstraZeneca vaccine outweigh any risks, several European countries have limited use to older age groups or suspended use altogether.

In answer to a question at the European Parliament in Strasbourg, French President Emmanuel Macron welcomed the move towards what he sees are more effective vaccines against new variants of COVID-19, calling it "pragmatic". "We are vaccinating with this vaccine (AstraZeneca) in France and in Europe. We must continue to do this because it will help us get out of the crisis." he said.

"But for future orders, in order to respond in particular to variants, we see that other vaccines are now more effective, so this signals a European pragmatism which I welcome."

The European Union signed a new contract with Pfizer-BioNTech to receive 1.8 billion doses of COVID-19 vaccines for 2021-2023, to cover booster shots, donations and reselling of doses, the European Commission said on Friday.

An increase in prices for second generation vaccines could be justified by the extra research required and potential changes to industrial equipment, Breton said.

"There may be a little extra cost but I will let the competent authorities unveil it in due course," he told France Inter radio. (Reporting by Sybille de La Hamaide; Editing by Toby Chopra, Andrew Cawthorne and Raissa Kasolowsky)


ę Reuters 2021
All news about ASTRAZENECA PLC
04:08aER+/ HER2-VE BREAST CANCER PIPELINE : Emerging Therapies and Key pharma players ..
AQ
01:30aASTRAZENECAá : COVID-19 Approved In Pakistan For People Under 40
MT
06/15US, EU Vow to Provide COVID-19 Vaccine to Two-Thirds of World's Population by..
MT
06/15INDIAN SCIENTISTS : We didn't back doubling of vaccine dosing gap
RE
06/15European Stocks End Higher as Investors Wait for Fed
MT
06/15ASTRAZENECAá : How UK PM Johnson decided to delay COVID reopening
RE
06/15INDIAN SCIENTISTS : We didn't back doubling of vaccine dosing gap
RE
06/15GLOBAL MARKETS LIVE : General Electric, AstraZeneca, H&M, Bohoo, Implenia...
06/15Mitsubishi UFG Says Sterling's Positive Outlook Clouded by Spread of COVID-19..
MT
06/15WALL STREET STOCK EXCHANGE : Inflation and pricing power
More news
Financials (USD)
Sales 2021 31 008 M - -
Net income 2021 4 562 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 33,9x
Yield 2021 2,43%
Capitalization 154 B 154 B -
EV / Sales 2021 5,32x
EV / Sales 2022 4,67x
Nbr of Employees 76 100
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 132,34 $
Last Close Price 117,47 $
Spread / Highest target 45,5%
Spread / Average Target 12,7%
Spread / Lowest Target -18,1%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC13.91%154 316
JOHNSON & JOHNSON4.52%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.7.55%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.8.10%204 582